Alzheimer’s drugs should be prescribed like statins to stave off dementia, one of Britain’s leading neuroscientists has said.

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart ...

Two teams of scientists have recently come up with potential breakthroughs with preventing a serious side effect of Parkinson ...

Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

Hearing loss is associated with a higher risk of developing Parkinson disease, although hearing aids may help reduce risk.

Dr James Pickett, Head of Research at Alzheimer’s Society, warned commonly-prescribed drugs that treat conditions including ...

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.

Intra-Cellular Therapies is developing Lenrispodun for the treatment of patients with Parkinson's Disease in a phase 2 study.

Aug. 5, 2024 — A research team examined the effect of Ecklonia cava polyphenols on the prevention of Parkinson's disease. It was found that the oral intake of the seaweed antioxidants restores ...

AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease.

A recent scientific study has issued warnings that certain commonly prescribed medications could elevate the risk of dementia ...